HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trialAntonio Llombart‐Cussac, Aleix Prat, Montserrat Muñoz-Mateu et al.|The Lancet Oncology|2017Cited by 340
First-Line Camizestrant for Emerging <i>ESR1</i> -Mutated Advanced Breast CancerFrançois‐Clément Bidard, Nicholas C. Turner, Erica L. Mayer et al.|New England Journal of Medicine|2025Cited by 106
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluationAleix Prat, PierFranco Conte, Valentina Guarneri et al.|The Lancet Oncology|2020Cited by 75
Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibitionFrancesca Mateo, E. Castellà, Miguel Ángel Pujana et al.|Oncogene|2016Cited by 39